Estimated read time: 3-4 minutes
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
[STK]
[IN] CPC HHP HOU HEA
[SU] WOM
-- WITH PHOTO -- TO BUSINESS EDITORS:
Innocutis Introduces Dexter the Dystrophic Nail to Educate the Public
on Nail Dystrophy and How Nuvail Can Help Treat This Common Problem
CHARLESTON, S.C., April 16, 2014 /PRNewswire/ -- Innocutis, a
specialty pharmaceutical company in Dermatologic and Podiatric
specialties, is pleased to announce that Nuvail [poly-ureaurethane,
16%] is currently the #1 Prescribed Brand for Nail Dystrophy in both
dermatology and podiatry. Nail Dystrophy affects a vast portion of the
U.S. population and the medical community has had limited treatment
options to effectively address this growing problem.
Photo - http://photos.prnewswire.com/prnh/20140415/73345
Photo - http://photos.prnewswire.com/prnh/20140415/73344
An animated social media campaign has been launched to educate on the
prevalence of nail dystrophy and NUVAIL as a viable treatment option.
The antagonist of healthy nails in this fun, light-hearted, social
media campaign is Dexter, the dystrophic nail. Who or what is Dexter?
Dexter epitomizes nail dystrophy by representing the splitting,
fragile and weak nail associated with dystrophic nails that many
patients experience. Innocutis hopes to educate the general public on
the various forms of nail dystrophy; most commonly being mycotic
(fungal), psoriatic and brittle nail syndrome (affecting as much as
20% of US population).
Nuvail addresses the signs and symptoms of nail dystrophy by
protecting and fortifying the nail plate. Nuvail is formulated to
mechanically support the damaged nail plate using a proprietary
polymer blend that creates a strong adhesion to the nail surface.
Nuvail's patented polymer creates a breathable barrier allowing for
oxygen transfer to the germinal matrix while blocking water
absorption; therefore, preventing the wet-dry cycle that commonly
leads to damaged nails.
Daily application of Nuvail also protects the nail from harm caused by
work activity such as direct abrasion, friction and over exposure to
water or chemicals. The clinical benefits of Nuvail have recently been
documented in a peer reviewed clinical study published by the Journal
of Drugs in Dermatology.
Innocutis hopes to show Dexter, the dystrophic nail doesn't stand a
fighting chance.
To meet Dexter, the dystrophic nail and learn how Nuvail can help
those that suffer from Dexter's dastardly forms, click on the video
linked below.
http://nuvail-rx.com/weak-brittle-nails/
Follow Dexter on Twitter: https://twitter.com/dystrophicnail
Like Dexter on Facebook:
https://www.facebook.com/DexterTheDystrophicNail
About Innocutis Holdings, LLC:
Innocutis is a pharmaceutical company specializing in the development
and commercialization of therapies focused on medical treatments of
dermatological conditions. We believe our focus on dermatologic
conditions sets us apart as a company that understands the growing
needs of the dermatology specialty. Our commitment is to be
best-in-class in skin-related therapies, providing clinicians with
improved solutions for the management of daily challenges experienced
in their practice.
Contact: Charles F. Jenkins VP Sales & Marketing 800-499-4468
Read more news from Innocutis Holdings, LLC.
SOURCE Innocutis Holdings, LLC
-0- 04/16/2014
/Photo: http://photos.prnewswire.com/prnh/20140415/73345
http://photos.prnewswire.com/prnh/20140415/73344
PRN Photo Desk, photodesk@prnewswire.com
CO: Innocutis Holdings, LLC
ST: South Carolina
IN: CPC HHP HOU HEA
SU: WOM
PRN
-- PH06123 --
0000 04/16/2014 12:35:00 EDT http://www.prnewswire.com
Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
